Results
AstraZeneca Pharma India Q1 Revenue Up 30% YoY
AstraZeneca Pharma India reported unaudited Q1 FY2026-27 revenue of ₹6,828 million, a 30% YoY growth driven by strong performance in Oncology, Biopharmaceuticals, and Rare Disease segments.
The Board
